Category Archives: Guest Blog

The Technologies Set to Transform Healthcare

By G. Steven Burrill, CEO, Burrill & Company. The promise of precision medicine is beginning to bear fruit as deadly diseases are made treatable, doctors use genetic information to guide treatment decisions, and the convergence of information, communications, and biological technology reinvents the practice of medicine. The arrival of this new age of medicine has […]
Also posted in Biotech, Global, healthcare, Op-Ed, Technology | Tagged , , , | Leave a comment

What Drives Patient Interest in Clinical Trials?

By Fred Gebhart. Recruiting patients remains one of the most difficult challenges clinical trial sponsors face. Recognizing that fewer than five percent of eligible adult patients enroll in therapeutic trials, many sponsors have turned to supplemental recruitment, the practice of pre-qualifying community-based patients for referral to clinical trial sites for screening. “The primary reason that […]
Also posted in patient education, R&D | Tagged , | Leave a comment

Strong IP Plans Essential for UK Life Sciences Clusters

By John Dean, Withers & Rogers LLP. Life sciences and biotech research clusters across the UK, including those linked to university research departments are benefiting from an improved funding climate and ongoing consolidation in the pharmaceutical sector. However, as big pharma companies increasingly vie for the best spin-out investment opportunities, those with strategic intellectual property […]
Also posted in Biotech, Europe, Global, IP, Strategy | Tagged , , , | Leave a comment

Value-Based Assessment in the UK: The Patient View

By Leela Barham. Patients are influential in the UK when it comes to access to medicines: their individual stories are highlighted in the media and the groups that represent them are credited with major policies. For example, the Rarer Cancer Foundation (RCF) has been credited in large part with the introduction of the Cancer Drugs […]
Also posted in Europe, Op-Ed, pricing | Tagged , , , , , , | Leave a comment

European Pharma Policy Reaches "New Level of Timidity"

By Peter O’ Donnell, Applied Clinical Trials. The European Union has managed to snatch defeat from the jaws of opportunity once more! A long-heralded document portentously entitled “Pharmaceutical industry: a strategic sector for the European economy,” and supposedly initiating a new start in long-term thinking about boosting the drug industry, squeezes the thinnest and weakest […]
Also posted in Europe, Op-Ed, Regulatory | Tagged , , | Leave a comment
  • Categories

  • Meta